Table 3 Urinary retinol binding protein levels following treatment with seliciclib

From: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

 

Urinary retinol binding protein (0.10–100.0 mg/mol creatinine)

 

Patient 20

Patient 21

Patient 22

Pretreatment

8.7

136.4

6.8

Day 3

59.2

44.7

7.9

Day 14

20.8

25.7

40.1

Back to article page